[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, Romano C, Vollaro M, Agostini B, Pignatelli C, De Vita F: Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum; 2004 Nov;47(11):1904-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.
  • PURPOSE: Early-stage colon cancer patients (Dukes A or B; pT1-T3 pNO pMO) are excluded from adjuvant chemotherapy following potentially curative surgery because they are expected to have good long-term survival.
  • This indicates that the conventional staging procedures may be unable to precisely predict cancer prognosis.
  • METHODS: In 65 early-stage colon cancers, we investigated by immunohistochemistry the role of molecular markers such as p27, p53, and vascular endothelial growth factor in identifying high-risk patients who may benefit from adjuvant treatments.
  • RESULTS: No clinicopathologic factor, namely Dukes stage, t parameter, number of resected nodes, and vascular or lymphatic invasion, was found be an independent significant predictor of disease-specific and disease-free survival.
  • In contrast, each molecular marker predicted survival and recurrence rates much better than the conventional Dukes staging system.
  • Nearly all cancer-related deaths were observed among patients whose colon cancers expressed all three molecular alterations.
  • Regardless of Dukes stage, the recurrence rate was found to increase with the increase in the number of molecular alterations.
  • Early-stage colon cancers expressing p27 down-regulation and high p53 and vascular endothelial growth factor immunoreactivity showed a 100 percent actuarial four-year recurrence rate.
  • CONCLUSIONS: Assessment of molecular alterations may be useful to identify a higher-risk group of early-stage colon cancer patients who may benefit from adjuvant chemotherapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622584.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


2. Morris EJ, Maughan NJ, Forman D, Quirke P: Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut; 2007 Oct;56(10):1419-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology.
  • OBJECTIVE: To identify by routine pathology which Dukes B colorectal cancer patients may benefit from chemotherapy.
  • METHOD: Retrospective study of the five year survival of colorectal cancer patients for whom colorectal pathology minimum datasets had been collected between 1997 and 2000 in the Yorkshire region of the UK.
  • The study population consisted of 1625 Dukes B and 480 Dukes C patients who possessed one positive node treated between 1997 and 2000.
  • The predictive ability of the Petersen prognostic model was investigated and survival of Dukes B patients with potentially high risk pathological features was compared to that of Dukes C patients with one positive node.
  • The index offered a statistically significant survival difference of 24.3% and 30.3% between high and low risk colon (p<0.01) and rectal cancer patients (p<0.01).
  • Survival of Dukes B patients with any of the high risk pathological factors or low nodal yields was lower than that of Dukes C patients who possessed one positive node.
  • CONCLUSION: Petersen's index discriminated between high and low risk Dukes B colorectal tumours, but inadequate pathological reporting diminished its ability to identify all high risk patients.
  • The survival of patients with any high risk feature was lower than the threshold for adjuvant therapy of one lymph node positive Dukes C colorectal cancer.
  • Chemotherapy may benefit patients with such features.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1803-9 [16971667.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1682-8 [11711742.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Gut. 2002 Jul;51(1):65-9 [12077094.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3999-4005 [12351597.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] J Cancer Educ. 2003 Summer;18(2):81-6 [12888381.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):133-8 [12844262.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):43-7 [14693834.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] J Clin Pathol. 1997 Feb;50(2):138-42 [9155695.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):266-7 [9215136.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7 [16172297.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2071-8 [16125926.001]
  • [Cites] Acta Oncol. 2005;44(8):904-12 [16332600.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] Dis Colon Rectum. 2006 Nov;49(11):1673-83 [17019656.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • (PMID = 17494107.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2000279
  •  go-up   go-down


3. Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer; 2005 Jan 31;92(2):259-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
  • Patients with mucinous colorectal cancer generally have worse prognoses than those with the nonmucinous variety.
  • The reason for this disparity is unclear, but may result from a differential response to adjuvant chemotherapy.
  • We examined known molecular markers for response to common chemotherapy in these two histological subtypes.
  • In all, 21 patients with mucinous and 30 with nonmucinous Dukes C colorectal cancer were reviewed for demographic data and outcome.
  • Quantitative expression levels of drug pathway genes were determined using TaqMan RT-PCR (5-fluorouracil (5-FU): TYMS, DPYD, ECGF1; oxaliplatin: GSTP1 (glutathione S-transferase pi), ERCC1 and 2; irinotecan: ABCB1, ABCG2, CYP3A4, UGT1A1, CES2, TOP1).
  • Mucinous colorectal cancer overexpresses markers of resistance to 5-FU and oxaliplatin.
  • The presence of mucin should be carefully evaluated in developmental trials of new agents for treating colorectal cancer.


Advertisement
4. Feliciotti F, Guerrieri M, Paganini AM, De Sanctis A, Campagnacci R, Perretta S, D'Ambrosio G, Lezoche E: Long-term results of laparoscopic versus open resections for rectal cancer for 124 unselected patients. Surg Endosc; 2003 Oct;17(10):1530-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of laparoscopic versus open resections for rectal cancer for 124 unselected patients.
  • BACKGROUND: Controversy continues to surround laparoscopic rectal resection for malignancy.
  • A longer follow-up period is required to evaluate the long-term efficacy of the procedure and its impact on survival.
  • The aims of this study were to compare long-term outcomes for unselected patients undergoing either laparoscopic or open rectal resection for cancer.
  • METHODS: A series of 124 unselected consecutive patients with rectal cancer, who underwent surgery by the same surgical team, have been included in this study.
  • All the patients underwent preoperative radiotherapy (5,040 cGy), performed in selected cases with chemotherapy (for patients younger than 70 years).
  • One laparoscopic patient was lost to follow-up evaluation, whereas three laparoscopic patients and one open patient died of causes not related to cancer.
  • Cumulative survival probability was 0.709 after laparoscopic resection after LR and 0.606 after open resection ( p = 0.162), whereas for Dukes' stages A, B, and C in the laparoscopic group versus the open group, it was 0.875 vs 0.889 ( p = 0.392), 0.722 vs 0.584 ( p = 0.199), and 0.500 vs 0.417 ( p = 0.320), respectively.
  • Long-term outcome after laparoscopic resection of rectal cancer was comparable with that after conventional resection.
  • [MeSH-major] Digestive System Surgical Procedures. Laparoscopy. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical / mortality. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Ileostomy / methods. Ileostomy / mortality. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Preoperative Care. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2005 Feb;19(2):296; author reply 297-8 [15549626.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):181-6 [10903594.001]
  • [Cites] Dig Surg. 1998;15(2):117-23 [9845573.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Zentralbl Chir. 2001 Apr;126(4):302-6 [11370393.001]
  • [Cites] Surg Endosc. 2001 Jun;15(6):600-8 [11591950.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):83-7 [9345361.001]
  • [Cites] Surg Endosc. 2000 Jul;14(7):612-6 [10948295.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1297-9 [7489148.001]
  • [Cites] Surg Endosc. 1998 Jul;12(7):963-7 [9632871.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):487-92 [10203080.001]
  • [Cites] World J Surg. 1999 Apr;23(4):397-405 [10030864.001]
  • [Cites] Surg Endosc. 2002 Apr;16(4):558-62 [11972187.001]
  • [Cites] J Formos Med Assoc. 1998 Jan;97(1):32-7 [9481062.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):963-70 [9715150.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):697-708 [10919014.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S35-46 [8831545.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):203-8 [11285969.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):97-8 [10773141.001]
  • [Cites] Dis Colon Rectum. 2001 Aug;44(8):1123-8 [11535851.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):148-54 [8620780.001]
  • [Cites] Surg Endosc. 1994 Aug;8(8):881-3 [7992154.001]
  • [Cites] Dis Colon Rectum. 1998 Jul;41(7):832-8 [9678367.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Semin Surg Oncol. 2000 Dec;19(4):396-403 [11241922.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):506-11 [10749610.001]
  • (PMID = 12874687.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Gallego-Plazas J, Menárguez-Pina F, Maestre-Peiró A, González-Orozco V, Andreu F, Escudero-Barea MJ, Morcillo MA: Feasibility of adequate resectable rectal cancer treatment in a third-level hospital. Clin Transl Oncol; 2009 Mar;11(3):172-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.
  • PURPOSE: The aim of this study was to determine the feasibility, concerning compliance to protocol and recommended clinical practice guidelines, as well as efficacy results of multidisciplinary treatment (surgery, radiotherapy and chemotherapy) of resectable rectal cancer in a third-level hospital devoid of radiotherapy and clinical oncology units.
  • PATIENTS AND METHODS: A retrospective, single-institution analysis was completed for 45 consecutive patients diagnosed with resectable rectal cancer who entered an officially proposed multidisciplinary treatment protocol from October 1998 to September 2003.
  • Adequacy of patient inclusion, according to clinical stage, was reviewed.
  • Neoadjuvant radiotherapy schedule, surgery procedures and adjuvant chemotherapy indication were assessed.
  • All treatment time intervals were analysed.
  • Finally, efficacy results are discussed and contextualised by comparison with results of clinical trials which support this treatment strategy.
  • RESULTS: According to an independent board review, 3 patients (6.7%) with stage I rectal cancer, 31 patients (68.9%) with stage II and 11 patients (24.4%) with stage III rectal cancer were included.
  • Median time from diagnosis to start of radiotherapy was 26.36 days (24.26- 28.57; CI 95%).
  • Median time from start of radiotherapy to surgery was 15.67 days (14.47-16.87; CI 95%).
  • Median time from completion of radiotherapy to surgery was 10.67 days (9.53-11.81; CI 95%).
  • Twenty-nine patients (64.4%) of the 45 that were initially included started adjuvant chemotherapy.
  • A statistically significant relationship between pathologic stage (grouped I-II vs. III) and the use of adjuvant chemotherapy was found (p=0.033; chi-square test).
  • Radiotherapy- and chemotherapy-induced toxicity did not differ from that previously reported.
  • With a median follow-up of 65.46 months, a total of 10 recurrences have been diagnosed, all of them in stage III patients.
  • CONCLUSION: Multidisciplinary treatment of resectable rectal cancer in a third-level hospital is feasible.
  • Although efficacy results are comparable to those previously reported in the literature, further improvements in clinical staging as well as in adjuvant chemotherapy indication are desirable.
  • [MeSH-major] Rectal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Longitudinal Studies. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2007 Nov;12(11):1309-18 [18055850.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1130-5 [9278661.001]
  • [Cites] Cancer. 1984 May 1;53(9):1811-8 [6423263.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1142-9 [12190680.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Radiology. 1989 Feb;170(2):319-22 [2643135.001]
  • [Cites] Eur J Cancer. 1994;30A(11):1602-6 [7530469.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):115-21 [15170648.001]
  • [Cites] AJR Am J Roentgenol. 1986 Apr;146(4):703-10 [3485343.001]
  • [Cites] Am J Surg. 2002 May;183(5):509-11 [12034382.001]
  • [Cites] Radiol Clin North Am. 1997 Mar;35(2):457-85 [9087214.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):889-95 [12081739.001]
  • [Cites] Cancer. 1989 Mar 15;63(6 Suppl):1026-30 [2465076.001]
  • [Cites] Aust N Z J Surg. 1994 Jul;64(7):457-63 [8010914.001]
  • [Cites] Radiology. 1986 Feb;158(2):347-53 [3941861.001]
  • [Cites] Br J Surg. 1985 Sep;72 Suppl:S64-6 [3899265.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):606-14 [3056288.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):796-801 [17211840.001]
  • [Cites] Br J Surg. 1988 Oct;75(10 ):1019-22 [3064866.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Suppl Tumori. 2005 May-Jun;4(3):S8 [16437871.001]
  • [Cites] Clin Transl Oncol. 2007 Mar;9(3):183-91 [17403630.001]
  • [Cites] Lancet. 1996 Dec 14;348(9042):1610-4 [8961990.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Nov;19(9):674-81 [17888639.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • (PMID = 19293055.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Biswal BM, Sain AH, Othman NH, Baba A: Adjuvant treatment in colorectal cancer. Experience from a referral center in eastern peninsular Malaysia. Trop Gastroenterol; 2002 Jul-Sep;23(3):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment in colorectal cancer. Experience from a referral center in eastern peninsular Malaysia.
  • BACKGROUND: Colorectal cancer is one of the most common malignancies in the West, but in Asia the incidence is low.
  • However in Malaysia, colorectal cancer is increasing with a reported figure of 15% of all cancer cases.
  • The present retrospective analysis was performed to document the effect of such therapy among patients with colorectal cancer in Malaysia.
  • MATERIALS AND METHODS: This is a retrospective study on the use of adjuvant treatment in colorectal cancers.
  • Patients with histopathological evidence of risk factors were subjected to adjuvant radiotherapy and/or chemotherapy.
  • Cancers confined to rectum and rectosigmoid were subjected to pelvic radiotherapy to a tumor dose of 45 Gy in 20 fractions over 4-week period.
  • 5-flurouracil based chemotherapy was predominantly offered for colonic cancers.
  • RESULTS: One hundred thirty patients with colorectal cancers received adjuvant treatment with a median age of 58 years (range 22-76 years).
  • Modified Dukes' stage B2 (28%) and C (38%) constituted the majority, which were distributed in rectum (40%), rectosigmoid (19%), and in the remaining colon (41%).
  • Following treatment, the 2-year actuarial survival was 28% and 54% in colon and rectum cancer respectively.
  • CONCLUSIONS: This study showed that colorectal cancer is not infrequent among Malays in this region and rectal cancers had better survival than the colonic cancers.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Fluorouracil / administration & dosage. Humans. Incidence. Malaysia / epidemiology. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12693156.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Wang WS, Chen PM, Chiou TJ, Liu JH, Fan FS, Lin TC, Jiang JK, Yang SH, Yen CC, Wang HS, Lin JK: Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan. Hepatogastroenterology; 2000 Nov-Dec;47(36):1590-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
  • BACKGROUND/AIMS: Preoperative CEA levels, depth of tumor penetration, and the number of positive lymph nodes were reported as independent factors prognostic of survival in colorectal cancer patients.
  • This study was carried out in an effort to evaluate the prognostic significance of these three factors in patients with Dukes' C colorectal cancer in Taiwan.
  • METHODOLOGY: Between 1992 and 1994, a total of 112 patients with node-positive colorectal cancer were evaluated retrospectively at the Veteran General Hospital-Taipei.
  • All patients underwent potentially curative surgery and received 5-fluorouracil based adjuvant chemotherapy.
  • Reference to the Dukes' classification was according to the classical criteria described in 1932 for carcinoma of the rectum and adapted for use in colonic tumors.
  • Using multivariate Cox analysis the number of positive lymph nodes, penetration of the bowel wall, and preoperative CEA levels were still found as independent prognostic factors in node-positive colorectal cancer patients.
  • CONCLUSIONS: Data obtained from our study indicates that preoperative CEA levels, depth of tumor penetration, and the number of positive lymph nodes were independent prognostic factors in Dukes' C colorectal cancer patients.
  • They could serve as appropriate modifications of the initial Dukes scheme in node-positive diseases.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149009.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


8. Petersen VC, Baxter KJ, Love SB, Shepherd NA: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut; 2002 Jul;51(1):65-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.
  • BACKGROUND AND AIMS: There is a need for objective easily determined pathological prognostic parameters in Dukes' B colon carcinoma to allow selection of such patients for further treatment as the role of adjuvant chemotherapy for these patients remains unclear.
  • This study was initiated to assess the influence of pathological factors on prognosis in an unselected prospective series of Dukes' B colonic cancer.
  • METHODS: The Gloucester Colorectal Cancer study, established in 1988, recruited more than 1000 cases.
  • Meticulous pathological assessment of the 268 Dukes' B colonic cancer resections in this series included evaluation of all pathological factors that could influence staging and prognosis.
  • CONCLUSIONS: The cumulative prognostic index allows apportionment of patients with Dukes' B colon cancer into defined prognostic groups, which in turn could allow more objective selection of patients for adjuvant therapy, especially as part of clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):564-71 [8625148.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):65-70 [9093709.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1096-102 [9097991.001]
  • [Cites] J Clin Pathol. 1997 Apr;50(4):266-7 [9215136.001]
  • [Cites] Support Care Cancer. 1997 Jul;5(4):318-21 [9257429.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1349-54 [9579845.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2135-44 [9610692.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):481-2 [9771453.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):849-55 [7490320.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):449-56 [10749603.001]
  • [Cites] Br J Surg. 1980 Jun;67(6):439-42 [7388345.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Histopathology. 1987 Mar;11(3):259-72 [2828216.001]
  • [Cites] J Clin Pathol. 1989 Feb;42(2):162-6 [2921357.001]
  • [Cites] Histopathology. 1989 Jun;14(6):613-20 [2759558.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] J Surg Oncol Suppl. 1991;2:36-41 [1909867.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [CommentIn] Gut. 2002 Jul;51(1):6-7 [12077080.001]
  • (PMID = 12077094.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1773289
  •  go-up   go-down


9. Thebo JS, Senagore AJ, Reinhold DS, Stapleton SR: Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum; 2000 Feb;43(2):155-9; discussion 159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients.
  • PURPOSE: Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions.
  • The purpose of this study was to determine whether K-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately.
  • Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of the K-ras gene were identified.
  • None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) with K-ras positive lymph nodes.
  • CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of the K-ras gene are at high risk for the development of nodal metastases.
  • Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy.
  • Therefore, K-ras mutational analysis should be considered for molecular staging of colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10696887.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm
  •  go-up   go-down


10. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, Poppema S, Buys CH, Plukker JT: Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum; 2001 Mar;44(3):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
  • PURPOSE: Mutations in K-ras and TP53 genes are common in colorectal cancer.
  • They affect biologic behavior and might influence chemotherapy susceptibility in these tumors.
  • We investigated whether the survival of patients with Dukes C colon cancer treated with adjuvant chemotherapy is influenced by K-ras and TP53 mutations.
  • METHODS: Mutation screening of the hot spots of the K-ras gene and of the evolutionarily conserved regions of the TP53 gene was performed by denaturing gradient gel electrophoresis technique in formalin-fixed paraffin-embedded specimens of 55 consecutive patients with Dukes C colon cancer treated with adjuvant 5-fluorouracil-based chemotherapy.
  • RESULTS: Alterations in the mutation hot spots of K-ras were found at codon 12 (n = 11) and 13 (n = 4) in 15 of the 55 carcinomas (27 percent).
  • Cancer-specific survival did not differ significantly between patients with K-ras or TP53 or both mutated and nonmutated tumors, respectively (log-rank test: K-ras, P = 0.72 and TP53, P = 0.77; K-ras and TP53, P = 0.8).
  • CONCLUSIONS: Patients with K-ras or TP53 or both mutated Dukes C colon tumors have the same survival as nonmutated tumors when treated with adjuvant chemotherapy.
  • These data suggest that mutations in K-ras or TP53 alone are not prognostic indicators in patients with Dukes C colon cancer receiving adjuvant 5-Fluorouracil-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / genetics. DNA Mutational Analysis. Fluorouracil / administration & dosage. Proto-Oncogene Proteins p21(ras) / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Codon. Combined Modality Therapy. Exons. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11289281.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol; 2009;48(3):368-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
  • BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
  • It was therefore decided to assess the role of adjuvant therapy with 5fluorouracil (5-FU) combined with levamisole (Lev) in a confirmatory randomised study.
  • MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
  • Therapy started with a loading course of bolus i.v.
  • RESULTS: There was no significant survival difference between the two groups at 5 years: Disease-free survival (DFS) was 73% after chemotherapy, 68% (p=0.24) in the control group, and corresponding cancer specific survival (CSS) 75% and 71%, respectively (p=0.69).
  • There was no difference between the two groups when analysed for colon and rectum separately.
  • However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
  • Toxicity was generally mild and acceptable with no drug related fatalities.
  • CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
  • Rectal cancer does not benefit from this regimen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Staging. Norway. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242829.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Labianca RF, Beretta GD, Pessi MA: Disease management considerations: disease management considerations. Drugs; 2001;61(12):1751-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is still a majorhealth and social problem.
  • However, many important advances in treatment have been made in the last 4 to 5 years, and more optimism is now justified both among clinicians and patients.
  • In surgically resectable disease, adjuvant chemotherapy has been clearly demonstrated as able to increase overall survival in patients with colon cancer Dukes' stage C, whereas the role of medical treatment in patients with Dukes' stage B colon cancer is still controversial.
  • For rectal cancer, the best adjuvant treatment seems to be represented by radiotherapy (better if administered preoperatively) combined with chemotherapy (usually based on modulated or continuously infused 5-FU).
  • In advanced disease, many new drugs have recently emerged: the most active regimens are those combining an optimal modality of 5-FU administration (i.e. continuous infusion) and one of the most active innovative compounds (irinotecan or oxaliplatin).
  • The role of the oral drugs (e.g. tegafur/uracil, capecitabine) is still under investigation as is the combination of agents excluding 5-FU.
  • It is now recognised that first-line treatment must be offered to all suitable pa- tients, even though asymptomatic, and that a second-line therapy (chiefly with irinotecan) is of value in many patients with cancer that progresses during treatment with 5-FU.
  • From a strategic point of view, the best sequence of drugs/regimens has not yet been defined, while the duration and timing of chemotherapy is still a matter for clinical research.
  • Finally, there is an increasing interest in the role of biological prognostic factors as an aid to a patient-tailored therapy, both in the adjuvant setting and in advanced disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Humans. Liver / physiopathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):459-65 [2957943.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Radiother Oncol. 1996 Aug;40(2):127-35 [8884966.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1338-42 [10658524.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):35-41 [9102259.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):555-63 [10880038.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):581-5 [8879371.001]
  • [Cites] Lancet. 1995 Feb 11;345(8946):349-53 [7845115.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2296-300 [7964943.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1996 Mar;14 (3):709-15 [8622015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2528-33 [9667274.001]
  • [Cites] Ann Oncol. 1994 Mar;5(3):233-7 [8186170.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):955-60 [9816066.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):267-74 [7542021.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1421-30 [10526268.001]
  • [Cites] Postgrad Med J. 1996 Aug;72(850):464-9 [8796208.001]
  • [Cites] Ann Surg. 1997 Feb;225(2):193-201 [9065296.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):961-5 [9006748.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):893-900 [1735081.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):425-32 [2926468.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Oncology (Williston Park). 1997 Mar;11(3):295-300, 305; discussion 306 passim [9109124.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1413-20 [11142481.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):353-4 [10972363.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):904-11 [1588370.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):252-8 [8614003.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):625-30 [2066758.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Acta Oncol. 1992;31(6):645-51 [1281650.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • (PMID = 11693464.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 70
  •  go-up   go-down


13. Sarid D, Wigler N, Gutkin Z, Merimsky O, Leider-Trejo L, Ron IG: Cutaneous and subcutaneous metastases of rectal cancer. Int J Clin Oncol; 2004 Jun;9(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous and subcutaneous metastases of rectal cancer.
  • The occurrence of cutaneous metastatic disease from colorectal cancer is uncommon and typically signifies widespread disease with poor prognosis.
  • The woman was found to have an adenocarcinoma of the rectum, a Dukes' C lesion, extending over the entire rectal wall into the perirectal fat; five of eight regional lymph nodes showed metastases.
  • Adjuvant radiotherapy followed by chemotherapy was administered for about 1 year.
  • A subcutaneous lump on the left abdominal wall found 16 months postoperatively was metastatic of rectal origin.
  • A metastatic adenocarcinoma of rectal origin was found in a single left lower axillary node 26 months later.
  • Computerized tomography (CT) examination 5 years after the first presentation of the rectal tumor and almost 4 years after the diagnosis of abdominal skin metastases disclosed recurrent pelvic disease with severe left hydronephrosis.
  • Treatment by systemic chemotherapy was partially successful, but she died 8 months after this chemotherapy was initiated.
  • [MeSH-major] Adenocarcinoma / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Abdominal Wall / pathology. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Subcutaneous Tissue / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15221607.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Platell C, Lim D, Tajudeen N, Tan JL, Wong K: Dose surgical sub-specialization influence survival in patients with colorectal cancer? World J Gastroenterol; 2003 May;9(5):961-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose surgical sub-specialization influence survival in patients with colorectal cancer?
  • AIM: To perform a review of patients with colorectal cancer to a community hospital and to compare the risk-adjusted survival between patients managed in general surgical units versus a colorectal unit.
  • METHODS: The study evaluated all patients with colorectal cancer referred to either general surgical units or a colorectal unit from 1/1996 to 6/2001.
  • These variables included age, ASA score, disease stage, emergency surgery, adjuvant chemotherapy and/or radiotherapy, disease location, and surgical unit.
  • Patients in the colorectal group were more likely to have rectal cancer and Stage I cancers, and less likely to have Stage II cancers.
  • Survival regression analysis identified age, ASA score, disease stage, adjuvant chemotherapy, and treatment in a colorectal unit (Hazards ratio: 0.67; 95 % CI: 0.53 to 0.84, P =0.0005), as significant independent predictors of survival.
  • CONCLUSION: The results suggest that there may be a survival advantage for patients with colon and rectal cancers being treated within a specialist colorectal surgical unit.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Surgery. Female. General Surgery. Hospitals, Community. Hospitals, Teaching. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome. Western Australia

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4611405
  •  go-up   go-down


15. Koda K, Miyazaki M, Sarashina H, Suwa T, Saito N, Suzuki M, Ogawa K, Watanabe S, Kodaira S, Nakazato H: A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol; 2003 Jul;23(1):165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
  • Postoperative adjuvant chemotherapy reportedly improves advanced colorectal cancer patients' survival, however, it is necessary to assess what regimens are useful.
  • Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer.
  • 5'-DFUR is metabolized to 5-fluorouracil (5-FU) by thymidine phosphorylase existing in tumor at high concentrations, suggesting high 5-FU levels in tumor tissues and lesser complications.
  • They had diagnosed colorectal cancer of TNM stages II and III, and underwent macroscopic curative resection.
  • Patients were prestratified into colon or rectum cancer and allocated into either 5'-DFUR (5'-DFUR 460 mg/m(2)/day + PSK 3 g/day) or 5-FU (5-FU 115 mg/m(2)/day + PSK 3 g/day) group by dynamic randomization (stratification factors such as depth of tumor, degree of lymph node metastasis, and location of tumor).
  • Drugs were orally administered daily from postoperative week 2 to 54, with 6 mg/m(2) mitomycin C at operation and following days.
  • Although no differences in overall survival curves were detected, multivariate analysis showed that 5'-DFUR + PSK regimen was a significantly better prognostic factor in patients with Dukes B or C (risk ratio, 1.451; p=0.048); with tumor depth of pT3 or pT4 (risk ratio, 1.568; p=0.020).
  • For patients with advanced colorectal cancer, 5'-DFUR + PSK therapy may possibly be more useful than 5-FU + PSK, but further study is required.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Floxuridine / therapeutic use. Fluorouracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792790.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antimetabolites, Antineoplastic; 0 / Immunosuppressive Agents; 039LU44I5M / Floxuridine; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


16. Yau T, Watkins D, Cunningham D, Barbachano Y, Chau I, Chong G: Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. Dis Colon Rectum; 2009 Apr;52(4):669-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
  • PURPOSE: The purpose of this study was to assess the longitudinal impact of stoma formation on the health-related quality of life of rectal cancer patients treated with adjuvant chemotherapy.
  • METHODS: Health-related quality of life data was prospectively collected in a randomized trial designed to compare 24 weeks of bolus 5-fluorouracil/leucovorin with 12 weeks of continuous 5-fluorouracil in patients with resected Dukes B and C colorectal cancer.
  • Health-related quality of life data was collected at baseline, during adjuvant treatment, and at one and three years after completion of chemotherapy.
  • RESULTS: Between 1993 and 2003, 186 rectal cancer patients were enrolled.
  • There was no significant difference in global health-related quality of life between patients with and patients without a stoma at any time point.
  • However, during adjuvant treatment, role (P = 0.04) and social (P = 0.005) functioning were significantly worse in stoma patients than in nonstoma patients.
  • Moreover, the impairment in social functioning persisted at one (P = 0.03) and three years (P = 0.04) after adjuvant chemotherapy.
  • CONCLUSION: Our results demonstrate important adverse effects of either temporary or permanent stoma formation on subsequent health-related quality of life in patients with rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colostomy. Quality of Life. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Postoperative Period

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404073.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Braat AE, Oosterhuis JW, de Vries JE, Tollenaar RA: Lymphatic staging in colorectal cancer: pathologic, molecular, and sentinel node techniques. Dis Colon Rectum; 2005 Feb;48(2):371-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic staging in colorectal cancer: pathologic, molecular, and sentinel node techniques.
  • PURPOSE: Accurate staging in colorectal cancer is important to predict prognosis and identify patients who could benefit from adjuvant therapy.
  • Patients with lymphatic metastasis, Stage III/Dukes C, are generally treated with adjuvant chemotherapy.
  • Still, patients without lymphatic metastasis do have relapse as high as 27 percent in five years in Dukes B2.
  • If these (micro)metastasis can be identified, these patients might benefit from adjuvant therapy.
  • RESULTS: We found 30 articles about sentinel node in colorectal cancer describing original series.
  • The sentinel node technique has been recently described for use in colorectal cancer.
  • Whether to treat patients with adjuvant therapy if occult (micro)metastasis are found needs to be proven in future studies.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812587.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


18. Kingston EF, Goulding H, Bateman AC: Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining. Dis Colon Rectum; 2007 Nov;50(11):1867-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining.
  • PURPOSE: This study was designed to test the hypothesis that highlighting vascular spaces with histochemical or immunohistochemical stains facilitates the identification of extramural and intramural vascular invasion in resected colorectal cancer specimens compared with routine hematoxylin and eosin staining.
  • METHODS: Archival tumor sections from 50 resected colorectal cancers, in which extramural vascular invasion was not seen within the original tissue sections, were stained with hematoxylin and eosin, elastic van gieson histochemistry, and immunohistochemistry for CD31 and CD34.
  • RESULTS: Vascular invasion was more commonly identified in Dukes C (pTanyN1/2) (vascular invasion seen in 24 of 25 cases by at least 1 method) than Dukes B tumors (pT3/4N0) (vascular invasion seen in 14 of 25 cases by at least 1 method).
  • Vascular invasion was identified in significantly more cases using elastic van gieson (24 cases; P = 0.0001), CD31 (18 cases; P = 0.0064), and CD34 (21 cases; P < 0.0001) than with hematoxylin and eosin alone (5 cases).
  • CONCLUSIONS: This study was novel in that it compared both histochemical and immunohistochemical methods for identifying vascular invasion in cases of colorectal cancer in which vascular invasion had not been identified during initial reporting.
  • Highlighting of endothelium significantly increases the observed incidence of vascular invasion in colorectal cancer compared with hematoxylin and eosin alone.
  • Elastic van gieson seemed sensitive for the presence of vascular invasion but with uncertain specificity.
  • The possibility that these immunohistochemical methods may identify a subset of patients with colorectal cancer who may benefit from chemotherapy warrants further study.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2008 Sep;51(9):1436-7; author reply 1438-9 [18594927.001]
  • (PMID = 17665249.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Coloring Agents; 0 / Fluorescent Dyes; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


19. Sahraoui S, Acharki A, Tawfiq N, Jouhadi H, Bouras N, Benider A, Kahlain A: [Colorectal cancer in patients younger than 40 years of age]. Cancer Radiother; 2000 Nov-Dec;4(6):428-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal cancer in patients younger than 40 years of age].
  • [Transliterated title] Cancers rectocoliques chez le sujet de moins de 40 ans.
  • A family history of colorectal cancer was noted in 5%.
  • The most frequent symptoms were bleeding and rectal pain.
  • The localisation of the tumour was the rectum in 70 cases.
  • According to the anatomopathological profile, Dukes stages C and D were the most frequent and mucosal adenocarcinoma was noted in 24 cases.
  • Seventy patients had surgery, associated with radiation therapy in 59 cases.
  • Adjuvant chemotherapy was given in 44 cases and palliative treatment in 17 cases.
  • Worse prognostic factors were mucosal adenocarcinoma, poor differentiated adenocarcinoma and Dukes C and D stages.
  • [MeSH-minor] Adult. Age of Onset. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Palliative Care. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11191849.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R, Gregor M: Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis; 2004 Jan;19(1):23-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
  • BACKGROUND: In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease.
  • Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.
  • Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors.
  • However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.
  • [MeSH-major] Carcinoma / genetics. Colorectal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):787-95 [8761300.001]
  • [Cites] Cancer Lett. 1997 Sep 16;118(1):29-35 [9310257.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):585-90 [7917901.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1855-64 [1532346.001]
  • [Cites] Oncogene. 1996 Jun 20;12(12):2641-9 [8700523.001]
  • [Cites] Eur J Cancer. 2000 May;36(8):1008-15 [10885605.001]
  • [Cites] Br J Cancer. 1997;75(6):903-9 [9062414.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):593-9 [10080604.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):802-6 [9081357.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):988-92 [7862679.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):544-9 [10749909.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):560-7 [10682666.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):197-201 [10448259.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] J Pathol. 1992 Apr;166(4):329-30 [1517889.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):758-64 [1419618.001]
  • [Cites] Arch Surg. 1993 May;128(5):526-31; discussion 531-2 [8489386.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):549-57 [11330582.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):830-7 [10370622.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):488-92 [10690528.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1842-7 [9667656.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1745-50 [10561211.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Feb;9(2):183-6 [9058631.001]
  • [Cites] Oncology. 1998 May-Jun;55(3):249-57 [9560058.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):162-7 [11307149.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1257-62 [7779721.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1306-10 [7577041.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1405-11 [9815825.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1375-81 [10334521.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Gut. 1998 May;42(5):669-72 [9659162.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):491-7 [8814697.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):883-90 [10370632.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Biochem Pharmacol. 1995 May 17;49(10):1419-26 [7763285.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 15;85(24):1978-80 [8246279.001]
  • [Cites] J Pathol. 1996 Dec;180(4):364-70 [9014855.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10 ):2371-6 [9796967.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1343-9 [11350904.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1180-7 [9609754.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:101-10 [8526339.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):325-8 [10037181.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):9-14 [7802584.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):399-402 [8347496.001]
  • [Cites] Dis Colon Rectum. 1994 Jun;37(6):527-34 [8200229.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1760-70 [10561213.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1188-95 [9609755.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):364-72; discussion 372-3 [11289282.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):796-804 [9126737.001]
  • [Cites] Semin Oncol. 1999 Dec;26(6):589-605 [10606252.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):216-23 [8688324.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3839-44 [9042267.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):755-60 [9645744.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Cancer. 2000 Nov 15;89(10 ):2025-37 [11066042.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Hum Mol Genet. 1996 Sep;5(9):1245-52 [8872463.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1465-9 [9552053.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] J Cell Sci. 1972 Mar;10(2):471-86 [4259666.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):785-90 [9221853.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):358-63 [11289281.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1581-6 [7731713.001]
  • [Cites] J Pathol. 1994 Jan;172(1):5-12 [7931827.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2541-8 [10375100.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1055-60 [7576991.001]
  • [Cites] World J Surg. 1997 Feb;21(2):210-3 [8995081.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2584-8 [3458220.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2203-6 [3829006.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1996-9 [10473077.001]
  • [Cites] Br J Cancer. 1998;77(3):466-71 [9472645.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):190-3 [10496341.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(16):2053-60 [11044641.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):1009-22 [7707100.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):310-5 [9221810.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):971-5 [10910245.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):681-7 [8158699.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3907-12 [11268475.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1729-35 [8608570.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):260-3 [7678832.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):293-6 [8054278.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1053-6 [7907781.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):727-36 [11241240.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2696-701 [8874329.001]
  • [Cites] Oncogene. 1995 Aug 17;11(4):647-52 [7651727.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1053-6 [11038045.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1821-6 [10470121.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4797-802 [11156237.001]
  • [Cites] Science. 1993 May 7;260(5109):810-2 [8484120.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1176-81 [7587760.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):233-44 [9010096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):29-35 [9588914.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] J Pathol. 1999 May;188(1):14-7 [10398134.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] J Surg Oncol. 1994 Sep;57(1):57-64 [7914949.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1197-202 [10971428.001]
  • [Cites] Br J Cancer. 1997;75(1):87-93 [9000603.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):921-8 [11040179.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):239-44 [11300331.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1110-7 [8757190.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Br J Cancer. 1991 Feb;63(2):317-9 [1997114.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 1):5405-12 [3931905.001]
  • [Cites] Gut. 1994 Nov;35(11):1627-31 [7828987.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Gut. 1998 Sep;43(3):383-7 [9863484.001]
  • [Cites] Environ Health Perspect. 1991 Jun;93:125-31 [1685441.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1814-9 [10760757.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):903-8 [10070888.001]
  • [Cites] Cell. 1996 Aug 23;86(4):543-52 [8752209.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):57-64 [8419262.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):635-9 [8631411.001]
  • (PMID = 12827409.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Tumor Suppressor Protein p53; U3P01618RT / Fluorouracil
  • [Number-of-references] 152
  •  go-up   go-down


22. Borie F, El Nasser M, Herrero A, Gras-Aygon C, Daures JP, Tretarre B, CRISAP-LR: [Impact of the French consensus guidelines on the management of colonic and rectal cancer: a population-based study]. J Chir (Paris); 2008 May-Jun;145(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of the French consensus guidelines on the management of colonic and rectal cancer: a population-based study].
  • [Transliterated title] Impact des conférences de consensus sur la prise en charge du cancer du côlon et du rectum.
  • AIM: To compare the management of colorectal cancer (CRC) before and after the French consensus conferences of rectal cancer (RC) in 1994 and colonic cancer (CC) in 1998.
  • METHODS: From 344 CCR incident cases in 1992 and 545 in 2000, patient characteristics, tumor data, and diagnostic and treatment modalities were collected to compare the management of CRC.
  • No trends were observed in disease stage at diagnosis or rate of resection.
  • For CC with Dukes stage C and D, the use of chemotherapy increased significantly: for Dukes Stage C from 45% in 1992 to 55% in 2000; for Dukes Stage D from 37% in 1992 to 67% in 2000.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772733.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Shirouzu K, Ogata Y, Araki Y: Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer. Dis Colon Rectum; 2004 Sep;47(9):1442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer.
  • It is unclear whether autonomic nerve preservation is suitable curative procedure.
  • We clarify the significance of autonomic nerve preservation for an advanced lower rectal cancer.
  • In either Dukes A+B or Dukes C disease, the TME-P(+) group did not increase local recurrence or decrease ten-year disease-free survival compared with the TME-P(-) group of Period 1975 to 1984.
  • CONCLUSIONS: Autonomic nerve preservation is oncologically and functionally excellent and suitable for almost all patients with advanced lower rectal cancer.
  • Intensive chemotherapy is needed for patients whose autonomic nerves were killed in suspicion of nerve invasion.
  • [MeSH-major] Autonomic Nervous System / injuries. Lymph Node Excision. Neoplasm Recurrence, Local. Postoperative Complications / prevention & control. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Sexual Dysfunction, Physiological / etiology. Survival Analysis. Treatment Outcome. Urination Disorders / etiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486739.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sutoh I, Kohno H, Nakashima Y, Hishikawa Y, Tabara H, Tachibana M, Kubota H, Nagasue N: Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers. Dis Colon Rectum; 2000 Feb;43(2):221-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Because the status of the inherent drug-resistance of colorectal cancers remains obscure, human colorectal cancers with no neoadjuvant therapy were retrospectively investigated regarding the expression of three drug-resistant proteins: metallothionein, glutathione S-transferase-pi, and P-glycoprotein.
  • METHODS: Paraffin-embedded tissues of 130 colorectal cancers (Dukes A, 20; B, 49; C, 41; D, 20) obtained by surgical resections from 1982 to 1989 were used.
  • The data were compared with clinicopathologic features (Dukes A-D) and patients' prognosis (Dukes AC).
  • A total of 120 (86 percent) expressed at least one drug-resistant protein.
  • Rectal cancers positively expressed P-glycoprotein and three proteins more frequently.
  • The disease-free survival rates of patients with Dukes A through C cancer with positive staining for one, two, and three proteins were 100, 94, and 83 percent (at 1 year); 100, 72, and 51 percent (at 3 years); and 94, 66, and 38 percent (at 5 years), respectively (Kaplan-Meier with log-rank test; P = 0.016).
  • In the multivariate Cox analysis, age, Dukes stage, tumor size, and glutathione S-transferase-pi were independent prognostic factors.
  • CONCLUSIONS: The patients with concurrent expression of drug-resistant proteins in their cancers had worse prognoses.
  • Examining drug-resistant proteins in colorectal cancers may be useful in selecting adjuvant chemotherapy and in predicting prognosis more accurately.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease-Free Survival. Female. Glutathione S-Transferase pi. Humans. Immunoenzyme Techniques. Male. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10696897.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / P-Glycoprotein; 9038-94-2 / Metallothionein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


25. Salas-Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M, Santamaría S, Zamora JB: Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int; 2009 Dec;25(12):1073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases.
  • BACKGROUND: Carcinoma of the colon and rectum is rare in the pediatric age group, and usually presents with an advanced stage disease bearing a poor prognosis.
  • Colorectal carcinoma should be considered in children with signs of intestinal obstruction, alteration in bowel habits, gastrointestinal bleeding and chronic abdominal pain.
  • METHODS: Between 1974 and 2007, 11 patients were identified and treated for colorectal carcinoma at the Oncology Unit.
  • The medical records were studied to analyze the age, sex, clinical presentation, diagnostic procedures, extent of disease (Dukes staging), treatment, histological types, and outcome.
  • Predisposing diseases and syndromes were encountered in three children, (1 with Turner's syndrome and two with adenomatous familial polyposis).
  • Abdominal pain, acute intestinal obstruction, rectal bleeding and weight loss were the commonest symptoms.
  • Surgical procedures were done in 11 patients (incomplete resection with segmental resection in 4 patients, complete resection in the other 4, and biopsy alone in 3 patients).The predominant histological type was mucinous carcinoma.
  • Seven patients received adjuvant chemotherapy, all of whom did not survive.
  • CONCLUSIONS: Colorectal carcinoma in children is very uncommon and could be easily misdiagnosed, resulting in advanced stage disease at diagnosis.
  • Because radical surgery which is the mainstay of treatment is possible only in patients with early stage disease, a high level of awareness and early diagnosis are critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Antineoplastic Agents / therapeutic use. Colectomy / methods. Colonic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Chemotherapy, Adjuvant. Child. Colonoscopy. Costa Rica / epidemiology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Prognosis. Retrospective Studies. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):39-41 [15654277.001]
  • [Cites] Cancer. 1958 Jul-Aug;11(4):855-7 [13561255.001]
  • [Cites] Surg Gynecol Obstet. 1962 Apr;114:438-42 [13898554.001]
  • [Cites] J Pediatr Surg. 1976 Dec;11(6):967-71 [1003308.001]
  • [Cites] Clin Genet. 1987 Jan;31(1):35-44 [3568432.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] Pediatrics. 1963 Oct;32:558-71 [14069097.001]
  • [Cites] J Chemother. 2002 Jun;14(3):301-8 [12120887.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1085-9; discussion 1089-90 [1403541.001]
  • [Cites] Eur J Pediatr Surg. 2003 Feb;13(1):66-8 [12664421.001]
  • [Cites] Dis Colon Rectum. 1976 Sep;19(6):529-34 [183939.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):952-5 [4016687.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1322-6 [3971300.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1499-504 [10549756.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):919-21 [1640344.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1188-93 [8308690.001]
  • [Cites] Arch Surg. 1970 Apr;100(4):527-31 [4190476.001]
  • [Cites] Dis Colon Rectum. 1981 Jan-Feb;24(1):25-8 [7472098.001]
  • [Cites] Surgery. 1983 Mar;93(3):409-14 [6600855.001]
  • [Cites] Am J Surg. 1958 Jul;96(1):47-53 [13545485.001]
  • [Cites] Surg Gynecol Obstet. 1974 Feb;138(2):169-70 [4810853.001]
  • [Cites] Br J Surg. 1984 Apr;71(4):272-7 [6704677.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1560-2 [14605580.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2464-72 [200342.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):209-11 [17255833.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5808-14 [18089879.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1189-91 [2553912.001]
  • [Cites] South Med J. 1976 Jan;69(1):24-7 [1246645.001]
  • (PMID = 19816697.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Ito K, Nakazato H, Koike A, Takagi H, Saji S, Baba S, Mai M, Sakamoto J, Ohashi Y, Study Group of Immunochemotherapy with PSK for Colon Cancer: Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis; 2004 Mar;19(2):157-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
  • BACKGROUND AND AIMS: The efficacy of a biological response modifier polysaccharide K in adjuvant immunochemotherapy was evaluated in primary colon cancer patients with macroscopic Dukes' C after curative resection.
  • Group P received immunochemotherapy, oral PSK (3 g per day) followed by oral 5-FU (200 mg/body per day), while group C received only intermittent chemotherapy, oral 5-FU (200 mg per day) followed by 4-week rest.
  • RESULTS: Survival for cancer death was significantly higher in group P than in group C, but there was no difference in 7-year disease-free survival or overall survival had.
  • CONCLUSION: Repeated alternating administration with PSK followed by 5-FU can improve survival for cancer death.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Immunologic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Proteoglycans / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Aug 1;58(3):603-10 [3731019.001]
  • [Cites] Immunol Lett. 1992 Feb 15;31(3):241-5 [1372283.001]
  • [Cites] Anticancer Res. 1992 May-Jun;12 (3):645-8 [1622120.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):255-8 [7762991.001]
  • [Cites] Jpn J Clin Oncol. 1995 Jun;25(3):91-103 [7596054.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):123-30 [1735313.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]
  • [Cites] Cancer Immunol Immunother. 1995 Mar;40(3):152-6 [7728773.001]
  • [Cites] Cancer Immunol Immunother. 1998 Mar;46(1):14-20 [9520287.001]
  • [Cites] Stat Med. 1982 Apr-Jun;1(2):121-9 [7187087.001]
  • [Cites] Int J Immunopharmacol. 1988;10 (4):415-23 [3170055.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Altern Med Rev. 2000 Feb;5(1):4-27 [10696116.001]
  • [Cites] J Urol. 1991 May;145(5):1082-7 [2016797.001]
  • [Cites] Gan. 1981 Apr;72 (2):293-9 [7286551.001]
  • [Cites] Br Med J. 1970 Feb 28;1(5695):541-4 [5435189.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] Cancer Treat Rep. 1985 Jul-Aug;69(7-8):739-42 [4016784.001]
  • [Cites] Biotherapy. 1991;3(4):287-95 [1786194.001]
  • [Cites] Lancet. 1994 May 7;343 (8906):1122-6 [7910230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):275-81 [7606203.001]
  • (PMID = 13680286.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antimetabolites, Antineoplastic; 0 / Proteoglycans; 3X48A86C8K / krestin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Robinson B, Frizelle F, Dickson M, Frampton C: Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts. N Z Med J; 2005 Feb 25;118(1210):U1323
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts.
  • AIM: To compare clinicopathological variables, management, and outcome of two cohorts of unselected patients treated for colorectal cancer (CRC) at Christchurch Hospital, New Zealand in 1993-94 and 1998-99.
  • RESULTS: 356 patients in 1993-94 and 317 patients in 1998-99 had a confirmed diagnosis of adenocarcinoma of the colon or rectum.
  • At the minimum follow-up time of 42 months, 54% (40% of CRC) of the 356 patients in the first cohort, and 36% (26% of CRC) of the 317 patients in the second cohort had died.
  • The Kaplan-Meier survival curves showed significant improvement in 1998-99 overall, as well as for Dukes stages A plus B, stage C, and stage D disease.
  • Computed tomography (CT) scan-staging increased from 11.3% to 62.8%.
  • On multivariate analysis, cohort, stage, vascular/lymphatic invasion, and elective surgery were independent prognostic factors for disease-specific mortality.
  • Over the 5 years (1993-94 to 1998-99), surgery by consultant increased from 44% to 82%, adjuvant chemotherapy for Dukes stage C increased from 21% to 45%, and chemotherapy for metastatic disease increased from 2.4% to 23% of stage D and from 2.5% to 36.5% of those patients who developed metastases.
  • CONCLUSION: The improvement in outcome is attributed to more specialised surgery, more frequent CT scan staging, and greater use of chemotherapy.
  • [MeSH-minor] Analysis of Variance. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / utilization. Cohort Effect. Elective Surgical Procedures. Humans. Multivariate Analysis. Neoplasm Staging. New Zealand / epidemiology. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed / utilization. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Z Med J. 2005 Feb 25;118(1210):U1330 [15776102.001]
  • (PMID = 15776099.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Stelzner F, von Mallek D, Ruhlmann J, Biersack HJ: [PET-CT studies of metastasizing cancer of the colon and rectum. Variability of tumor aggressiveness as a micro-evolutionary process of cancer stem cells with predetermined prognosis]. Chirurg; 2009 Jul;80(7):645-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PET-CT studies of metastasizing cancer of the colon and rectum. Variability of tumor aggressiveness as a micro-evolutionary process of cancer stem cells with predetermined prognosis].
  • [Transliterated title] PET-CT-Untersuchungen zur Stammzellkarzinogenese im Kolorektalbereich. Malignitätsvariabilität als mikroevolutionärer Prozess mit festgelegter Prognose.
  • Formation of cancer stem cells which are both rare and variably therapy-resistant marks the beginning of a new disease without precursors.
  • In vitro studies have shown that hybrid cancers which behave in a similar way to Dukes A, B or C cancers in vivo can be produce by horizontal gene transfer.
  • The primary tumor acts as the supplier of cancer stem cells for metastases which appear in different organs.
  • When chemotherapy is administered the distribution of metastases in different organs appears dependent of the response or non-response of cancer stem cells to this therapy.
  • Large numbers of colorectal carcinomas existed for the same time duration before death (15 years) independent of the malignancy grade.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Colorectal Neoplasms / pathology. Image Processing, Computer-Assisted. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Neoplastic Stem Cells / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Biological Evolution. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Drug Resistance, Neoplasm / radiation effects. Gene Transfer Techniques. Humans. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Organ Specificity. Probability Theory. Prognosis. Radiotherapy, Adjuvant


29. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI: Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum; 2001 Apr;44(4):523-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma.
  • PURPOSE: The goal was to investigate the prognostic value of various molecular markers like CEA, Cyclin D1, Bcl-2, c-Myc, p53, p21ras, Ki-67, CD44, Factor VIII-related antigen, cytokeratin-19, adenoma antigen, and prolactin in patients with Dukes B and Dukes C colorectal adenocarcinoma.
  • The patients with colorectal cancer were followed for a period of five years or their death within that period.
  • Besides Dukes stage, multivariate analysis indicated a significantly reduced relapse-free survival in patients expressing CD44 and cytokeratin-19 (P < 0.005).
  • Similarly, besides Dukes stage, multivariate analysis indicated a significantly poor overall survival in patients expressing CD44, cytokeratin-19 and prolactin (P < 0.01).
  • In patients with Dukes B disease, only cytokeratin-19 and CD44 expression attained statistical significance (P < 0.05), whereas in patients with Dukes C disease, CD44, p21ras- and c-Myc expression attained statistical significance (P < 0.018).
  • Also, a multivariate analysis in relation to treatment given was performed using CD44 and cytokeratin-19.
  • CONCLUSION: Besides Dukes stage, multivariate analysis of all the studied molecular markers showed that patients expressing CD44 and cytokeratin-19 had a significantly reduced relapse-free and poor overall survival.
  • Moreover, patients expressing both these markers (CD44 and cytokeratin-19) had the lowest significant relative risk for developing recurrence than patients with both markers negative when treated with surgery followed by adjuvant chemotherapy as compared with patients treated with surgery alone.
  • Thus, in patients with colorectal cancer, immunohistochemical localization of CD44 and cytokeratin-19 may be included as a part of routine pathologic evaluation along with conventional prognostic factors.


30. Borie F, El Nasser M, Herrero A, Gras-Aygon C, Crisap-Lr, Daures JP, Tretarre B: [Not Available]. J Chir (Paris); 2008 May;145(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Impact des conférences de consensus sur la prise en charge du cancer du côlon et du rectum: Étude de population.
  • Impact of the French consensus guidlines on the management of colonic and rectal cancer: A population-based study F. Borie, M.
  • Gras-Aygon, CRISAP-LR, J.-P. Daures, B.
  • Tretarre Aim: To compare the management of colorectal cancer (CRC) before and after the French consensus conferences of rectal cancer (RC) in 1994 and colonic cancer (CC) in 1998.
  • METHODS: From 344 CCR incident cases in 1992 and 545 in 2000, patient characteristics, tumor data, and diagnostic and treatment modalities were collected to compare the management of CRC.
  • No trends were observed in disease stage at diagnosis or rate of resection.
  • For CC with Dukes stage C and D, the use of chemotherapy increased significantly: for Dukes Stage C from 45% in 1992 to 55% in 2000; for Dukes Stage D from 37% in 1992 to 67% in 2000.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22805258.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Grothey A, Kellermann L, Schmoll HJ: [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. Med Klin (Munich); 2002 May 15;97(5):270-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].
  • [Transliterated title] Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland. Ergebnisse einer multizentrischen Dokumentation von Therapiealgorithmen.
  • BACKGROUND: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer.
  • PATIENTS AND METHODS: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998.
  • Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented.
  • RESULTS: Only 63.4% of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1%) and without (42.6%) oncological departments (p < 0.01).
  • Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5%) patients < 70 years, but only 57 of 121 (47.1%) > 70 years underwent adjuvant therapy.
  • 78.4% of patients with UICC IV colorectal cancer (91.8% university hospitals, 76.8% hospital with, 50% without oncological departments, 66.7% rehabilitation clinics, 82.4% private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57%, 5-FU/FA infusion 20%, 5-FU mono 15%).
  • CONCLUSION: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey.
  • In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients.
  • --In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Critical Pathways. Quality Assurance, Health Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Germany. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078387.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst; 2000 Mar 1;92(5):388-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
  • BACKGROUND: The conviction that postoperative radiotherapy and chemotherapy represent an acceptable standard of care for patients with Dukes' B (stage II) and Dukes' C (stage III) carcinoma of the rectum evolved in the absence of data from clinical trials designed to determine whether the addition of radiotherapy results in improved disease-free survival and overall survival.
  • PATIENTS AND METHODS: Eligible patients (n = 694) with Dukes' B or C carcinoma of the rectum were enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol R-02 from September 1987 through December 1992 and were followed.
  • They were randomly assigned to receive either postoperative adjuvant chemotherapy alone (n = 348) or chemotherapy with postoperative radiotherapy (n = 346).
  • All female patients (n = 287) received 5-FU plus LV chemotherapy; male patients received either MOF (n = 207) or 5-FU plus LV (n = 200).
  • RESULTS: The average time on study for surviving patients is 93 months as of September 30, 1998.
  • Postoperative radiotherapy resulted in no beneficial effect on disease-free survival (P =.90) or overall survival (P =.89), regardless of which chemotherapy was utilized, although it reduced the cumulative incidence of locoregional relapse from 13% to 8% at 5-year follow-up (P =.02).
  • CONCLUSIONS: The addition of postoperative radiation therapy to chemotherapy in Dukes' B and C rectal cancer did not alter the subsequent incidence of distant disease, although there was a reduction in locoregional relapse when compared with chemotherapy alone.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Staging. Semustine / administration & dosage. Sex Factors. Survival Analysis. Time Factors. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2000 Mar 1;92(5):361-2 [10699060.001]
  • (PMID = 10699069.001).
  • [ISSN] 0027-8874
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA12027; United States / NCI NIH HHS / CA / CA37377
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 13909-09-6 / Semustine; 5J49Q6B70F / Vincristine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; MOF protocol
  •  go-up   go-down


33. Taal BG, Van Tinteren H, Zoetmulder FA, NACCP group: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer; 2001 Nov 16;85(10):1437-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
  • Based on the first favourable results of adjuvant therapy of 5FU plus levamisole in Dukes C colonic cancer in 1990, we conducted a prospective trial.
  • 1029 patients were randomised to receive one year 5FU plus levamisole or no further treatment following curative surgery for stage II or III colon (n = 730) or rectal cancer (n = 299).
  • 45% were in stage II and 55% in stage III.
  • With a median follow-up of 4 years and 9 months a significant reduction in odds of death (25%, SD 9%, P = 0.007) was observed for those with adjuvant treatment (65% at 5 year) compared to the observation group (55%).
  • Improved relative survival was present in stage III (56% vs 44%), and in stage II patients (78% vs 70%).
  • In rectal cancer a non-significant difference in disease-free or overall survival was observed.
  • Distant metastases developed in 76%, while local recurrence alone occurred in 14%.
  • An early start of adjuvant treatment (< 4 weeks) did not affect results.
  • In conclusion, one year 5FU plus levamisole was of benefit in stage II and III colonic cancer; in rectal cancer a significant positive effect could not be demonstrated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality. Rectal Neoplasms / drug therapy. Rectal Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Levamisole / administration & dosage. Male. Middle Aged. Neoplasm Staging. Patient Compliance. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 15;67(8):2042-8 [2004322.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] JAMA. 1988 Jun 24;259(24):3571-8 [3286920.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]
  • [CommentIn] Br J Cancer. 2002 May 6;86(9):1524-5; author reply 1525-6 [11986790.001]
  • [CommentIn] Br J Cancer. 2001 Nov 16;85(10):1422-4 [11720422.001]
  • (PMID = 11720425.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Scotland
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2363941
  •  go-up   go-down


34. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen PM: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol; 2000 Jan;30(1):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
  • BACKGROUND: Preoperative carcinoembryonic antigen (CEA) level is considered as a factor predictive of survival in colorectal cancer patients.
  • This study was carried out in an effort to evaluate the prognostic significance of preoperative CEA levels of patients with colorectal cancer in Taiwan.
  • 5-Fluorouracil-based adjuvant chemotherapy was administered if the patients had Dukes' C disease.
  • Reference to the Dukes' classification was according to the classical criteria described in 1932 for carcinoma of the rectum and adapted for use in colonic tumors.
  • By multivariate Cox analysis, lymph node metastases (p = 0.003), penetration of the bowel wall (p = 0.0001) and preoperative CEA levels (p = 0.0001) were found to be independent prognostic factors in colorectal cancer patients.
  • CONCLUSIONS: The data from our study indicate that in addition to lymph node metastases and penetration of the bowel wall, the preoperative CEA levels are also an independent prognostic factor in non-metastatic colorectal cancer patients after curative surgery.
  • This could serve as an appropriate modification to the initial Dukes' scheme in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Colonic Neoplasms / blood. Rectal Neoplasms / blood
  • [MeSH-minor] Age Factors. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Colon / pathology. Female. Fluorouracil / therapeutic use. Forecasting. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Rectum / pathology. Retrospective Studies. Sex Factors. Survival Rate. Taiwan

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2000 Nov;30(11):522-3 [11155925.001]
  • (PMID = 10770562.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC, Belin B: Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum; 2001 Mar;44(3):364-72; discussion 372-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
  • PURPOSE: The aim of this study was to determine whether tumor location proximal or distal to the splenic flexure is associated with distinct molecular patterns and can predict clinical outcome in a homogeneous group of patients with Dukes B (T3-T4, N0, M0) colorectal cancer.
  • It has been hypothesized that proximal and distal colorectal cancer may arise through different pathogenetic mechanisms.
  • Although p53 and Ki-ras gene mutations occur frequently in distal tumors, another form of genomic instability associated with defective DNA mismatch repair has been predominantly identified in the proximal colon.
  • METHODS: A total of 126 patients with a lymph node-negative sporadic colon or rectum adenocarcinoma were prospectively assessed with the endpoint of death by cancer.
  • No patient received either radiotherapy or chemotherapy. p53 protein was studied by immunohistochemistry using DO-7 monoclonal antibody, and p53 and Ki-ras gene mutations were detected by single strand conformation polymorphism assay.
  • Nuclear p53 staining was found in 57 tumors (47 percent), and was more frequent in distal than in proximal tumors (55 vs. 21 percent; chi-squared test, P < 0.001).
  • Distal colon tumors and rectal tumors exhibited similar molecular patterns and showed no difference in clinical outcome.
  • In comparison with distal colorectal cancer, proximal tumors were found to be statistically significantly different on the following factors: mucinous content (P = 0.008), degree of histologic differentiation (P = 0.012), p53 protein expression, and gene mutation (P = 0.001 and 0.01 respectively).
  • Finally, patients with proximal tumors had a marginally better survival than those with distal colon or rectal cancers (log-rank test, P = 0.045).
  • CONCLUSION: In this series of Dukes B colorectal cancers, p53 protein expression was an independent factor for survival, which also correlated with tumor location.
  • Eighty-six percent of p53-positive tumors were located in the distal colon and rectum.
  • Distal colon and rectum tumors had similar molecular and clinical characteristics.
  • Location of the neoplasm in reference to the splenic flexure should be considered before group stratification in future trials of adjuvant chemotherapy in patients with Dukes B tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Single-Stranded Conformational. Prospective Studies. Rectum / pathology. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11289282.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


36. Vather R, Sammour T, Zargar-Shoshtari K, Metcalf P, Connolly A, Hill A: Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer. Int J Colorectal Dis; 2009 Mar;24(3):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer.
  • BACKGROUND: Mortality from cancer recurrence in Dukes B patients is approximately 25-30%.
  • Outcome in Dukes B patients improves in direct relation to the number of lymph nodes examined.
  • Examining fewer lymph nodes risks understaging and also such patients are less likely to receive chemotherapy.
  • The aim of this study was to assess the impact of the number of lymph nodes examined on recurrence and mortality in Dukes B colon cancers.
  • MATERIALS AND METHODS: A retrospective database was constructed of 328 consecutive patients who underwent resection for Dukes B colorectal cancer between January 1993 and December 2001 at Middlemore Hospital.
  • Patients with incomplete data, previous colorectal cancer, or perioperative deaths were excluded as were cases of rectal cancer.
  • Data for the remaining 216 patients was subjected to multivariate and logistic regression analysis with 'patient death' or 'cancer recurrence' (CRec5) within 5 years as endpoints.
  • CONCLUSION: Examination of more than 16 lymph nodes is associated with a significant reduction in cancer recurrence.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Demography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Recurrence. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Colorectal Dis. 2008 Feb;10(2):157-64 [17477849.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] Dis Colon Rectum. 1994 Apr;37(4):373-6; discussion 376-7 [8168417.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Cancer Prev Control. 1997 Oct;1(4):304-19 [9765754.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):903-9 [14527909.001]
  • (PMID = 18716784.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An intriguing feature of this case is an ulcerated jejunal carcinoma which was metastatic rather than synchronous carcinoma.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • Palliative pancolectomy and jejunal tumour resection with chemotherapy was offered to him.
  • The challenges of managing a hereditary cancer syndrome in a resource poor country are highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down






Advertisement